insights_auto
Hvorfor har GNLX gått opp? 2,40%?
Gå mer i dybdenchevron_right
GNLX:NASDAQ
Genelux Corp
2,56 USD
arrow_upward
+2,40%(+0,060) 1 D
9. okt., 16:00:01 GMT-4 · USD
search
Alle symboler
| Symbol | Pris | Endring | Endring (%) |
|---|
insights_autoGenererer viktig statistikk for GNLX …
Åpne
2,48 USD
Høy
2,57 USD
Lav
2,47 USD
Markedsverdi
115,83 mill.
Snittvolum
275,44k
Volum
154,65k
52 u høy
8,54 USD
52 u lav
2,29 USD
EPS
−0,87 USD
Beta
0,59
Utestående aksjer
45,24 mill.
Antall ansatte
26
Åpne
2,48 USD
Høy
2,57 USD
Lav
2,47 USD
Markedsverdi
115,83 mill.
Snittvolum
275,44k
Volum
154,65k
52 u høy
8,54 USD
52 u lav
2,29 USD
EPS
−0,87 USD
Beta
0,59
Utestående aksjer
45,24 mill.
Antall ansatte
26
Nyhetssaker
Fra nettkilder og nyhetspartnere
https://www.dars.gov.et/
·
for 1 uke siden
Genelux Corporation (GNLX) Slips 0.40% to $2.52 as Shares Hold Above Near-Term Support - Momentum Surge Alerts
Profil
Genelux Corporation is a publicly traded late clinical-stage company developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
Om Genelux Corp
Administrerende direktør-
Ansatte26
Grunnlagt2001
HovedkontorWestlake Village, California, USA
Sektor-
Nettstedgenelux.com